Leonie Kraft
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Leonie Kraft has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Severin Schricker
Department of Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart, Auerbachstr. 110, 70376 Stuttgart, Germany
9 shared publications - Moritz Schanz
Department of Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart, Auerbachstr. 110, 70376 Stuttgart, Germany
8 shared publications - Joerg Latus
Department of Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart, Auerbachstr. 110, 70376 Stuttgart, Germany
6 shared publications Jörg Latus
Robert Bosch Hospital Department of Internal Medicine and Nephrology Stuttgart
4 shared publicationsAndrea Schwab
Department of General Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart , Stuttgart
3 shared publicationsJoerg Latus
Department of General Internal Medicine and Nephrology, Robert Bosch Hospital Stuttgart , Stuttgart
3 shared publications
Latest Publications
- Open Access
- 24 September 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (10) , 1234
Reduced Peritoneal NRF2 Immunoreactivity in Encapsulating Peritoneal Sclerosis and Its Implications for Redox Homeostasis
Peritoneal dialysis (PD) is an effective modality of renal replacement therapy that provides patients with a high degree of autonomy. However, its long-term use is limited by the detrimental effects of PD fluids on the structure and function of the peritoneal membrane, ultimately leading to a loss of dialysis efficacy. Disruption of redox homeostasis plays a central role in these pathological changes, highlighting the importance of endogenous defense mechanisms in maintaining membrane integrity. Nuclear factor erythroid 2–related factor 2 (NRF2) is a key transcription factor regulating cellular antioxidant and cytoprotective responses. However, its immunoreactivity and localization in the peritoneal tissue of PD patients and patients with encapsulating peritoneal sclerosis (EPS) have not been well characterized. Therefore, we analyzed peritoneal biopsies from healthy controls, pre-dialysis patients, PD patients, and EPS patients. Immunohistochemical analysis demonstrated significantly reduced NRF2 immunoreactivity in patients with EPS compared with all other study groups. In contrast, nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) immunoreactivity was increased in PD and EPS patients. These results suggest that dysregulation of the NRF2–NFκB axis may be involved in peritoneal membrane injury, which warrants its further investigation as a potential target for preserving peritoneal membrane integrity during long-term PD.
- 24 September 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (10) , 1234
Open AccessReduced Peritoneal NRF2 Immunoreactivity in Encapsulating Peritoneal Sclerosis and Its Implications for Redox Homeostasis
Peritoneal dialysis (PD) is an effective modality of renal replacement therapy that provides patients with a high degree of autonomy. However, its long-term use is limited by the detrimental effects of PD fluids on the structure and function of the peritoneal membrane, ultimately leading to a loss of dialysis efficacy. Disruption of redox homeostasis plays a central role in these pathological changes, highlighting the importance of endogenous defense mechanisms in maintaining membrane integrity. Nuclear factor erythroid 2–related factor 2 (NRF2) is a key transcription factor regulating cellular antioxidant and cytoprotective responses. However, its immunoreactivity and localization in the peritoneal tissue of PD patients and patients with encapsulating peritoneal sclerosis (EPS) have not been well characterized. Therefore, we analyzed peritoneal biopsies from healthy controls, pre-dialysis patients, PD patients, and EPS patients. Immunohistochemical analysis demonstrated significantly reduced NRF2 immunoreactivity in patients with EPS compared with all other study groups. In contrast, nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) immunoreactivity was increased in PD and EPS patients. These results suggest that dysregulation of the NRF2–NFκB axis may be involved in peritoneal membrane injury, which warrants its further investigation as a potential target for preserving peritoneal membrane integrity during long-term PD.
- Open Access
- 19 August 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (8) , 1032
N-Acetylcysteine Protects HPMCs from High-Glucose-Induced Oxidative DNA Damage
Peritoneal dialysis (PD) is an effective renal replacement therapy; however, its long-term use is limited by the detrimental effects of glucose-based PD fluids on the peritoneal membrane, contributing to fibrosis and ultrafiltration failure. Previous studies have demonstrated that high-glucose exposure promotes oxidative DNA damage through upregulation of thioredoxin-interacting protein (TXNIP) expression, resulting in reduced thioredoxin (Trx) activity. This study investigated strategies to reduce oxidative stress in human peritoneal mesothelial cells exposed to high glucose concentrations. TXNIP expression, Trx activity, intracellular oxidative stress levels, and oxidative DNA damage were analyzed. High-glucose exposure caused a dose-dependent increase in TXNIP expression, a 5–15% reduction in Trx activity, and increased intracellular oxidative stress levels and oxidative DNA damage. Pre-treatment with the ROS scavenger N-acetylcysteine (NAC) reduced these effects. These findings demonstrate that glucose-induced TXNIP upregulation disrupts cellular redox homeostasis, resulting in increased intracellular oxidative stress and oxidative damage. Antioxidant compounds may therefore represent promising therapeutic strategies to protect the peritoneal membrane and improve long-term outcomes in PD.
- 19 August 2026
- Published by MDPI AG in Antioxidants
- Vol. 15 (8) , 1032
Open AccessN-Acetylcysteine Protects HPMCs from High-Glucose-Induced Oxidative DNA Damage
Peritoneal dialysis (PD) is an effective renal replacement therapy; however, its long-term use is limited by the detrimental effects of glucose-based PD fluids on the peritoneal membrane, contributing to fibrosis and ultrafiltration failure. Previous studies have demonstrated that high-glucose exposure promotes oxidative DNA damage through upregulation of thioredoxin-interacting protein (TXNIP) expression, resulting in reduced thioredoxin (Trx) activity. This study investigated strategies to reduce oxidative stress in human peritoneal mesothelial cells exposed to high glucose concentrations. TXNIP expression, Trx activity, intracellular oxidative stress levels, and oxidative DNA damage were analyzed. High-glucose exposure caused a dose-dependent increase in TXNIP expression, a 5–15% reduction in Trx activity, and increased intracellular oxidative stress levels and oxidative DNA damage. Pre-treatment with the ROS scavenger N-acetylcysteine (NAC) reduced these effects. These findings demonstrate that glucose-induced TXNIP upregulation disrupts cellular redox homeostasis, resulting in increased intracellular oxidative stress and oxidative damage. Antioxidant compounds may therefore represent promising therapeutic strategies to protect the peritoneal membrane and improve long-term outcomes in PD.
- Open Access
- 14 July 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Chronic Pruritus in Predialysis Chronic Kidney Disease: Prevalence, Phenotype and Temporal Patterns in a Prospective Cohort.
CKD-associated pruritus (CKD-aP) is a burden some symptom with incompletely understood pathophysiology and limited predialysis data. In this prospective observational study, 95 adult nondialysis CKD patients (stages G1-G5) were followed for up to 36 months (232 observations), 86 patients were analysed after exclusion of chronic dermatological conditions. Chronic pruritus (≥6 weeks) was assessed using a numerical rating scale (NRS) and anatomical mapping. Chronic pruritus occurred in 26 of 86 patients (30.2%), with numerically higher prevalence in advanced CKD (G3b-5 : 32.8% vs G1-3a: 22.7%), whereas intensity was numerically higher in early CKD (median 8 vs 5). The back, legs and head/ face were most frequently affected, consistent with the bilateral, nondermatomal pattern described in dialysis populations. Among patients with repeated assessments, 19.0% showed an episodic trajectory and 7.6% had persistent pruritus. Multivariable logistic regression and generalized estimating equations (GEE) were used to identify independent predictors of chronic pruritus. No laboratory parameter, including PTH, was independently associated with pruritus. Dyslipidaemia was the only clinical characteristic significantly associated with pruritus status (69.2% vs 43.3%, p=0.035). Given the modest sample size, smaller effect estimates may have been missed. CKD-aP affects approximately 1 in 3 predialysis patients, follows an episodic course, and is not explained by any single biochemical marker, supporting multifactorial pathophysiology.
- 14 July 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessChronic Pruritus in Predialysis Chronic Kidney Disease: Prevalence, Phenotype and Temporal Patterns in a Prospective Cohort.
CKD-associated pruritus (CKD-aP) is a burden some symptom with incompletely understood pathophysiology and limited predialysis data. In this prospective observational study, 95 adult nondialysis CKD patients (stages G1-G5) were followed for up to 36 months (232 observations), 86 patients were analysed after exclusion of chronic dermatological conditions. Chronic pruritus (≥6 weeks) was assessed using a numerical rating scale (NRS) and anatomical mapping. Chronic pruritus occurred in 26 of 86 patients (30.2%), with numerically higher prevalence in advanced CKD (G3b-5 : 32.8% vs G1-3a: 22.7%), whereas intensity was numerically higher in early CKD (median 8 vs 5). The back, legs and head/ face were most frequently affected, consistent with the bilateral, nondermatomal pattern described in dialysis populations. Among patients with repeated assessments, 19.0% showed an episodic trajectory and 7.6% had persistent pruritus. Multivariable logistic regression and generalized estimating equations (GEE) were used to identify independent predictors of chronic pruritus. No laboratory parameter, including PTH, was independently associated with pruritus. Dyslipidaemia was the only clinical characteristic significantly associated with pruritus status (69.2% vs 43.3%, p=0.035). Given the modest sample size, smaller effect estimates may have been missed. CKD-aP affects approximately 1 in 3 predialysis patients, follows an episodic course, and is not explained by any single biochemical marker, supporting multifactorial pathophysiology.
- Open Access
- 1 June 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (7) , sfag181
Long-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors
Background: Sparsentan has emerged as a promising therapeutic option for immunoglobulin A nephropathy. However, data on its effectiveness in real-world settings, particularly in combination with sodium–glucose cotransporter 2 (SGLT2) inhibitors remain limited. In our previously published real-world cohort (n = 23), we demonstrated a significant reduction in proteinuria with concurrent SGLT2 inhibitor treatment. Here, we present 1-year follow-up data. Methods: After 1 year, 17 patients (74%) from the initial cohort remained on sparsentan therapy. As described previously, patients had been on stable, maximally tolerated renin–angiotensin system (RAS) inhibition and stable SGLT2 inhibitor therapy before replacement of RAS inhibition with sparsentan; eligibility required an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2 and a urine protein/creatinine ratio (UPCR) >0.75 g/g. Results: Baseline median (interquartile range) eGFR (Chronic Kidney Disease Epidemiology Collaboration) was 48 ml/min/1.73 m2 (34–66) and median UPCR was 1.55 g/g (0.90–1.85). At 1-year follow-up, UPCR remained significantly reduced (P = .0001) to a median of 0.54 g/g (0.34–0.76), corresponding to a relative reduction of 61% (45–95). The median chronic eGFR slope was −1.5 ml/min/1.73 m2 per year (−7.51 to +3.75) at follow-up. Conclusions: In this 1-year follow-up of our real-world cohort, sparsentan was associated with a significant and sustained reduction in proteinuria over 12 months, with a numerically less steep eGFR decline during follow-up, even in patients already receiving SGLT2 inhibitors.
- 1 June 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (7) , sfag181
Open AccessLong-term real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors
Background: Sparsentan has emerged as a promising therapeutic option for immunoglobulin A nephropathy. However, data on its effectiveness in real-world settings, particularly in combination with sodium–glucose cotransporter 2 (SGLT2) inhibitors remain limited. In our previously published real-world cohort (n = 23), we demonstrated a significant reduction in proteinuria with concurrent SGLT2 inhibitor treatment. Here, we present 1-year follow-up data. Methods: After 1 year, 17 patients (74%) from the initial cohort remained on sparsentan therapy. As described previously, patients had been on stable, maximally tolerated renin–angiotensin system (RAS) inhibition and stable SGLT2 inhibitor therapy before replacement of RAS inhibition with sparsentan; eligibility required an estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2 and a urine protein/creatinine ratio (UPCR) >0.75 g/g. Results: Baseline median (interquartile range) eGFR (Chronic Kidney Disease Epidemiology Collaboration) was 48 ml/min/1.73 m2 (34–66) and median UPCR was 1.55 g/g (0.90–1.85). At 1-year follow-up, UPCR remained significantly reduced (P = .0001) to a median of 0.54 g/g (0.34–0.76), corresponding to a relative reduction of 61% (45–95). The median chronic eGFR slope was −1.5 ml/min/1.73 m2 per year (−7.51 to +3.75) at follow-up. Conclusions: In this 1-year follow-up of our real-world cohort, sparsentan was associated with a significant and sustained reduction in proteinuria over 12 months, with a numerically less steep eGFR decline during follow-up, even in patients already receiving SGLT2 inhibitors.
- Open Access
- 19 May 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 66, 101728
Hantavirus Infections—Clinical Recognition and Diagnostic Challenges
- 19 May 2026
- Published by Elsevier in The Lancet Regional Health - Europe
- Vol. 66, 101728
Open AccessHantavirus Infections—Clinical Recognition and Diagnostic Challenges
- Open Access
- 18 March 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (1) , 20
Glucocorticoid-Related Adverse Events in ANCA-Associated Vasculitis
Introduction: Glucocorticoid (GC)-sparing treatment strategies, such as the C5a receptor antagonist avacopan, could potentially replace the need for long-term GC therapy in ANCA-associated vasculitis (AAV). Therefore, an assessment of GC-related morbidity is required to provide justification for such therapies. The aim of this study was to assess the incidence and management of common GC-related adverse events. Methods: In this single-center cohort study, medical records were screened for patients with a diagnosis of AAV admitted to the Robert Bosch Hospital (RBK) in Stuttgart, Germany. A total of 74 patients admitted for treatment of AAV between 2004 and 2023 were included. We assessed the dosage and duration of GC therapy used to treat AAV, as well as the incidence of new-onset and worsening arterial hypertension and diabetes mellitus, using over 150,000 individual medication time points for calculation of GC therapy. Additionally, incidence of infections and fractures was recorded. Results: Including relapses, 127 vasculitis events were observed during a median follow-up time of 8.3 years (IQR 5.3–10.6). Median duration of glucocorticoid therapy was 2.9 years (IQR 1.3–5.8). Regarding adverse events, 15 patients (20%) developed new-onset diabetes mellitus and a significantly higher cumulative GC dose was observed in patients requiring insulin therapy compared with those on oral antidiabetics (p = 0.02). Furthermore, 38 (51%) patients were diagnosed with new-onset arterial hypertension. Patients requiring escalation of antihypertensive therapy had significantly higher cumulative GC dose after a vasculitis event (p = 0.0001). A total of 325 infectious events occurred across 69 patients (93%) during follow-up, mostly requiring (85%; n = 277) hospital admission. Cumulative GC dose was significantly higher in patients with documented infections (p = 0.002). Conclusions: GC-related adverse events are common in patients with AAV. This study provides evidence on the incidence of presumably treatment-related harms in AAV and further promotes the importance of reduced-dose or even GC-free treatment approaches.
- 18 March 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (1) , 20
Open AccessGlucocorticoid-Related Adverse Events in ANCA-Associated Vasculitis
Introduction: Glucocorticoid (GC)-sparing treatment strategies, such as the C5a receptor antagonist avacopan, could potentially replace the need for long-term GC therapy in ANCA-associated vasculitis (AAV). Therefore, an assessment of GC-related morbidity is required to provide justification for such therapies. The aim of this study was to assess the incidence and management of common GC-related adverse events. Methods: In this single-center cohort study, medical records were screened for patients with a diagnosis of AAV admitted to the Robert Bosch Hospital (RBK) in Stuttgart, Germany. A total of 74 patients admitted for treatment of AAV between 2004 and 2023 were included. We assessed the dosage and duration of GC therapy used to treat AAV, as well as the incidence of new-onset and worsening arterial hypertension and diabetes mellitus, using over 150,000 individual medication time points for calculation of GC therapy. Additionally, incidence of infections and fractures was recorded. Results: Including relapses, 127 vasculitis events were observed during a median follow-up time of 8.3 years (IQR 5.3–10.6). Median duration of glucocorticoid therapy was 2.9 years (IQR 1.3–5.8). Regarding adverse events, 15 patients (20%) developed new-onset diabetes mellitus and a significantly higher cumulative GC dose was observed in patients requiring insulin therapy compared with those on oral antidiabetics (p = 0.02). Furthermore, 38 (51%) patients were diagnosed with new-onset arterial hypertension. Patients requiring escalation of antihypertensive therapy had significantly higher cumulative GC dose after a vasculitis event (p = 0.0001). A total of 325 infectious events occurred across 69 patients (93%) during follow-up, mostly requiring (85%; n = 277) hospital admission. Cumulative GC dose was significantly higher in patients with documented infections (p = 0.002). Conclusions: GC-related adverse events are common in patients with AAV. This study provides evidence on the incidence of presumably treatment-related harms in AAV and further promotes the importance of reduced-dose or even GC-free treatment approaches.
- Open Access
- 8 December 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (1)
Changing microbiology and outcomes of PD-associated peritonitis over four decades
Background: Peritoneal dialysis (PD)-associated peritonitis remains a major complication affecting patient outcomes and modality survival. This study aims to evaluate temporal trends in pathogen distribution and antibiotic susceptibility over four decades as well as clinical outcomes in PD-associated peritonitis. Methods: We retrospectively analyzed 832 peritonitis cultures of PD patients across four decades from 1979 to 2024 treated at Robert Bosch Hospital, Stuttgart (Germany). For longitudinal comparison of pathogen distribution and antibiotic susceptibility, the study period was divided into four time periods: P1 (1979–1992), P2 (1993–2003), P3 (2004–2014), and P4 (2015–2024). Clinical response and outcomes were assessed in P4. Results: Gram-positive bacteria was the most frequent causative organisms (56%), followed by Gram-negative bacteria (30%) and culture-negative peritonitis (CNP, 13%). Gram-negative peritonitis increased significantly in P4 compared to P1–P3, while coagulase-negative staphylococci (CNS) declined from 31% in P1 to 14% in P4 (P = .0446). Vancomycin susceptibility among Gram-positive organisms remained high, whereas cefazolin susceptibility changed over time. In P4, the overall cure rate was 63%, with the highest in gram-positive (72%) and lowest in polymicrobial peritonitis (43%). Regarding clinical outcomes, transition to permanent hemodialysis (HD) was significantly more frequent in Gram-negative than Gram-positive peritonitis (27% vs. 12%; P = .03). Both catheter removal and transition to permanent HD occurred significantly more often in polymicrobial peritonitis (54% and 40%) compared with Gram-positive (24% and 12%; P = .001 and P = .0008) and CNP (30% and 17%; P = .01 and P = .04). Regarding individual pathogens, Staphylococcus aureus (MSSA) was associated with a significantly higher catheter removal rate compared to other Gram-positive organisms. Conclusion: Our findings show temporal changes of microbiological spectrum of PD-associated peritonitis over four decades. Polymicrobial and Gram-negative peritonitis were associated with poorer outcomes, emphasizing the need for ongoing microbiological surveillance and antibiotic stewardship to optimize PD care.
- 8 December 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (1)
Open AccessChanging microbiology and outcomes of PD-associated peritonitis over four decades
Background: Peritoneal dialysis (PD)-associated peritonitis remains a major complication affecting patient outcomes and modality survival. This study aims to evaluate temporal trends in pathogen distribution and antibiotic susceptibility over four decades as well as clinical outcomes in PD-associated peritonitis. Methods: We retrospectively analyzed 832 peritonitis cultures of PD patients across four decades from 1979 to 2024 treated at Robert Bosch Hospital, Stuttgart (Germany). For longitudinal comparison of pathogen distribution and antibiotic susceptibility, the study period was divided into four time periods: P1 (1979–1992), P2 (1993–2003), P3 (2004–2014), and P4 (2015–2024). Clinical response and outcomes were assessed in P4. Results: Gram-positive bacteria was the most frequent causative organisms (56%), followed by Gram-negative bacteria (30%) and culture-negative peritonitis (CNP, 13%). Gram-negative peritonitis increased significantly in P4 compared to P1–P3, while coagulase-negative staphylococci (CNS) declined from 31% in P1 to 14% in P4 (P = .0446). Vancomycin susceptibility among Gram-positive organisms remained high, whereas cefazolin susceptibility changed over time. In P4, the overall cure rate was 63%, with the highest in gram-positive (72%) and lowest in polymicrobial peritonitis (43%). Regarding clinical outcomes, transition to permanent hemodialysis (HD) was significantly more frequent in Gram-negative than Gram-positive peritonitis (27% vs. 12%; P = .03). Both catheter removal and transition to permanent HD occurred significantly more often in polymicrobial peritonitis (54% and 40%) compared with Gram-positive (24% and 12%; P = .001 and P = .0008) and CNP (30% and 17%; P = .01 and P = .04). Regarding individual pathogens, Staphylococcus aureus (MSSA) was associated with a significantly higher catheter removal rate compared to other Gram-positive organisms. Conclusion: Our findings show temporal changes of microbiological spectrum of PD-associated peritonitis over four decades. Polymicrobial and Gram-negative peritonitis were associated with poorer outcomes, emphasizing the need for ongoing microbiological surveillance and antibiotic stewardship to optimize PD care.
- 10 October 2025
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
Clinical course up to 20 years after hantavirus infection
Background: The long-term consequences of nephropathia epidemica (NE), a mild form of hemorrhagic fever with renal syndrome caused by Puumala virus (PUUV), remain incompletely understood. Previous studies suggested possible kidney and cardiovascular complications, but large-scale, long-term data are lacking. Methods: In this study, we evaluated n = 156 individuals with a history of NE-associated acute kidney injury, up to 20 years after confirmed PUUV infection. Participants were followed up and underwent clinical and laboratory assessments including blood pressure measurement, kidney parameters, urinalysis and PUUV-specific serology. Participants with abnormalities in their kidney function during the first long-term follow-up were re-evaluated after 1 year. Results: Median time since NE was 156 (interquartile range 137–168) months. Chronic kidney disease (CKD) was diagnosed in 8% of participants. Hematuria was present in 6% of participants. Hypertension at follow-up was observed in 78% of individuals. PUUV-specific immunoglobulin G (IgG) antibodies remained detectable in all participants, although three individuals had levels below the positive ratio threshold. No IgM antibodies or cases of reinfection were identified. Conclusion: This is the largest and longest follow-up study of NE patients to date. Our findings do not support long-term kidney pathologies, or increased CKD incidence following acute NE. IgG antibodies persisted in all participants irrespective of duration of follow-up, with no evidence of reinfection. While hypertension was frequent, causality with prior hantavirus infection remains uncertain. These results suggest that long-term kidney complications after NE are uncommon.
- 10 October 2025
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
Clinical course up to 20 years after hantavirus infection
Background: The long-term consequences of nephropathia epidemica (NE), a mild form of hemorrhagic fever with renal syndrome caused by Puumala virus (PUUV), remain incompletely understood. Previous studies suggested possible kidney and cardiovascular complications, but large-scale, long-term data are lacking. Methods: In this study, we evaluated n = 156 individuals with a history of NE-associated acute kidney injury, up to 20 years after confirmed PUUV infection. Participants were followed up and underwent clinical and laboratory assessments including blood pressure measurement, kidney parameters, urinalysis and PUUV-specific serology. Participants with abnormalities in their kidney function during the first long-term follow-up were re-evaluated after 1 year. Results: Median time since NE was 156 (interquartile range 137–168) months. Chronic kidney disease (CKD) was diagnosed in 8% of participants. Hematuria was present in 6% of participants. Hypertension at follow-up was observed in 78% of individuals. PUUV-specific immunoglobulin G (IgG) antibodies remained detectable in all participants, although three individuals had levels below the positive ratio threshold. No IgM antibodies or cases of reinfection were identified. Conclusion: This is the largest and longest follow-up study of NE patients to date. Our findings do not support long-term kidney pathologies, or increased CKD incidence following acute NE. IgG antibodies persisted in all participants irrespective of duration of follow-up, with no evidence of reinfection. While hypertension was frequent, causality with prior hantavirus infection remains uncertain. These results suggest that long-term kidney complications after NE are uncommon.
- 1 January 2025
- Published by Georg Thieme Verlag KG
Niere, Elektrolyte und Säure-Basen-Haushalt
- 7 September 2023
- Published by Georg Thieme Verlag KG in Nephrologie Aktuell
- Vol. 27 (07) , 314-320
Shuntinterventionen bei stenosierten Hämodialyseshunts
Klassische Dialyseshunts repräsentieren die wichtigste Lebensader für Patienten, die sich einer dauerhaften Hämodialyse unterziehen müssen. Morbidität und Mortalität sind direkte Folgen der Dysfunktionalität oder des Verschlusses eines Dialyseshunts, wodurch maßgeblich die Lebensqualität der Patienten als auch deren Umfeld beeinträchtigt wird. Die häufigste Ursache für eine Funktionseinschränkung des Hämodialyseshunts ist eine Stenosierung entlang des Shuntverlaufs durch eine Intimahyperplasie. Eine damit meist einhergehende Thrombose kann in der weiteren Beeinträchtigung bis hin zum vollständigen Versagen und der potenziellen Aufgabe des gesamten Shunts resultieren. Funktionell wirksame Stenosen bedürfen einer zeitnahen Abklärung, und Shuntverschlüsse sind als Gefäßnotfall einer umgehenden, wenn möglich endovaskulären, Wiedereröffnung zuzuführen, um eine künftige Shuntfunktionalität zu sichern. Es existieren zahlreiche unterschiedliche Techniken zur perkutanen Rekanalisation. Dabei steht die Entfernung der ggf. ausgedehnten Thrombose im Vordergrund, um die ursächliche Stenose zu demaskieren und damit eine fokussierte Therapie zu ermöglichen. In den letzten Dekaden waren hierfür unterschiedlichste Thrombektomiekatheter verfügbar. Die klassische Ballondilatation ist weiterhin das wichtigste Verfahren zur Wiederherstellung der Shuntfunktionalität. Eine Verbesserung der Offenheitsrate lässt sich durch eine zusätzliche Beschichtung der Ballonoberfläche erreichen, wie es aus der Behandlung von Koronargefäßstenosen bekannt ist. Stents bzw. ummantelte Stents als Stentgraftprothesen werden erst nach mehrfach unzureichendem Behandlungsergebnis oder häufig wiederkehrenden Shuntstenosen bzw. Shuntverschlüssen insbesondere im Bereich des zentralvenösen Gefäßsegments verwendet. Article published online: 07 September 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 7 September 2023
- Published by Georg Thieme Verlag KG in Nephrologie Aktuell
- Vol. 27 (07) , 314-320
Shuntinterventionen bei stenosierten Hämodialyseshunts
Klassische Dialyseshunts repräsentieren die wichtigste Lebensader für Patienten, die sich einer dauerhaften Hämodialyse unterziehen müssen. Morbidität und Mortalität sind direkte Folgen der Dysfunktionalität oder des Verschlusses eines Dialyseshunts, wodurch maßgeblich die Lebensqualität der Patienten als auch deren Umfeld beeinträchtigt wird. Die häufigste Ursache für eine Funktionseinschränkung des Hämodialyseshunts ist eine Stenosierung entlang des Shuntverlaufs durch eine Intimahyperplasie. Eine damit meist einhergehende Thrombose kann in der weiteren Beeinträchtigung bis hin zum vollständigen Versagen und der potenziellen Aufgabe des gesamten Shunts resultieren. Funktionell wirksame Stenosen bedürfen einer zeitnahen Abklärung, und Shuntverschlüsse sind als Gefäßnotfall einer umgehenden, wenn möglich endovaskulären, Wiedereröffnung zuzuführen, um eine künftige Shuntfunktionalität zu sichern. Es existieren zahlreiche unterschiedliche Techniken zur perkutanen Rekanalisation. Dabei steht die Entfernung der ggf. ausgedehnten Thrombose im Vordergrund, um die ursächliche Stenose zu demaskieren und damit eine fokussierte Therapie zu ermöglichen. In den letzten Dekaden waren hierfür unterschiedlichste Thrombektomiekatheter verfügbar. Die klassische Ballondilatation ist weiterhin das wichtigste Verfahren zur Wiederherstellung der Shuntfunktionalität. Eine Verbesserung der Offenheitsrate lässt sich durch eine zusätzliche Beschichtung der Ballonoberfläche erreichen, wie es aus der Behandlung von Koronargefäßstenosen bekannt ist. Stents bzw. ummantelte Stents als Stentgraftprothesen werden erst nach mehrfach unzureichendem Behandlungsergebnis oder häufig wiederkehrenden Shuntstenosen bzw. Shuntverschlüssen insbesondere im Bereich des zentralvenösen Gefäßsegments verwendet. Article published online: 07 September 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany